A microfluidics platform for combinatorial drug screening on cancer biopsies

Federica Eduati, Ramesh Utharala, Dharanija Madhavan, Ulf Peter Neumann, Thomas Longerich, Thorsten Cramer, Julio Saez-Rodriguez, Christoph A. Merten

Onderzoeksoutput: Bijdrage aan tijdschriftTijdschriftartikelAcademicpeer review

24 Citaties (Scopus)

Uittreksel

Screening drugs on patient biopsies from solid tumours has immense potential, but is challenging due to the small amount of available material. To address this, we present here a plug-based microfluidics platform for functional screening of drug combinations. Integrated Braille valves allow changing the plug composition on demand and enable collecting >1200 data points (56 different conditions with at least 20 replicates each) per biopsy. After deriving and validating efficient and specific drug combinations for two genetically different pancreatic cancer cell lines and xenograft mouse models, we additionally screen live cells from human solid tumours with no need for ex vivo culturing steps, and obtain highly specific sensitivity profiles. The entire workflow can be completed within 48 h at assay costs of less than US$ 150 per patient. We believe this can pave the way for rapid determination of optimal personalized cancer therapies.

TaalEngels
Artikelnummer2434
Aantal pagina's13
TijdschriftNature Communications
Volume9
Nummer van het tijdschrift1
DOI's
StatusGepubliceerd - 22 jun 2018

Vingerafdruk

Preclinical Drug Evaluations
Microfluidics
Biopsy
Drug Combinations
Tumors
Screening
drugs
screening
platforms
cancer
plugs
braille
tumors
Heterografts
Pharmaceutical Preparations
Assays
Neoplasms
Workflow
Cells
Pancreatic Neoplasms

Citeer dit

Eduati, F., Utharala, R., Madhavan, D., Neumann, U. P., Longerich, T., Cramer, T., ... Merten, C. A. (2018). A microfluidics platform for combinatorial drug screening on cancer biopsies. Nature Communications, 9(1), [2434]. DOI: 10.1038/s41467-018-04919-w
Eduati, Federica ; Utharala, Ramesh ; Madhavan, Dharanija ; Neumann, Ulf Peter ; Longerich, Thomas ; Cramer, Thorsten ; Saez-Rodriguez, Julio ; Merten, Christoph A./ A microfluidics platform for combinatorial drug screening on cancer biopsies. In: Nature Communications. 2018 ; Vol. 9, Nr. 1.
@article{2de9004b94c14f829a0eca8a1bc7dc55,
title = "A microfluidics platform for combinatorial drug screening on cancer biopsies",
abstract = "Screening drugs on patient biopsies from solid tumours has immense potential, but is challenging due to the small amount of available material. To address this, we present here a plug-based microfluidics platform for functional screening of drug combinations. Integrated Braille valves allow changing the plug composition on demand and enable collecting >1200 data points (56 different conditions with at least 20 replicates each) per biopsy. After deriving and validating efficient and specific drug combinations for two genetically different pancreatic cancer cell lines and xenograft mouse models, we additionally screen live cells from human solid tumours with no need for ex vivo culturing steps, and obtain highly specific sensitivity profiles. The entire workflow can be completed within 48 h at assay costs of less than US$ 150 per patient. We believe this can pave the way for rapid determination of optimal personalized cancer therapies.",
author = "Federica Eduati and Ramesh Utharala and Dharanija Madhavan and Neumann, {Ulf Peter} and Thomas Longerich and Thorsten Cramer and Julio Saez-Rodriguez and Merten, {Christoph A.}",
year = "2018",
month = "6",
day = "22",
doi = "10.1038/s41467-018-04919-w",
language = "English",
volume = "9",
journal = "Nature Communications",
issn = "2041-1723",
publisher = "Nature Publishing Group",
number = "1",

}

Eduati, F, Utharala, R, Madhavan, D, Neumann, UP, Longerich, T, Cramer, T, Saez-Rodriguez, J & Merten, CA 2018, 'A microfluidics platform for combinatorial drug screening on cancer biopsies' Nature Communications, vol. 9, nr. 1, 2434. DOI: 10.1038/s41467-018-04919-w

A microfluidics platform for combinatorial drug screening on cancer biopsies. / Eduati, Federica; Utharala, Ramesh; Madhavan, Dharanija; Neumann, Ulf Peter; Longerich, Thomas; Cramer, Thorsten; Saez-Rodriguez, Julio; Merten, Christoph A.

In: Nature Communications, Vol. 9, Nr. 1, 2434, 22.06.2018.

Onderzoeksoutput: Bijdrage aan tijdschriftTijdschriftartikelAcademicpeer review

TY - JOUR

T1 - A microfluidics platform for combinatorial drug screening on cancer biopsies

AU - Eduati,Federica

AU - Utharala,Ramesh

AU - Madhavan,Dharanija

AU - Neumann,Ulf Peter

AU - Longerich,Thomas

AU - Cramer,Thorsten

AU - Saez-Rodriguez,Julio

AU - Merten,Christoph A.

PY - 2018/6/22

Y1 - 2018/6/22

N2 - Screening drugs on patient biopsies from solid tumours has immense potential, but is challenging due to the small amount of available material. To address this, we present here a plug-based microfluidics platform for functional screening of drug combinations. Integrated Braille valves allow changing the plug composition on demand and enable collecting >1200 data points (56 different conditions with at least 20 replicates each) per biopsy. After deriving and validating efficient and specific drug combinations for two genetically different pancreatic cancer cell lines and xenograft mouse models, we additionally screen live cells from human solid tumours with no need for ex vivo culturing steps, and obtain highly specific sensitivity profiles. The entire workflow can be completed within 48 h at assay costs of less than US$ 150 per patient. We believe this can pave the way for rapid determination of optimal personalized cancer therapies.

AB - Screening drugs on patient biopsies from solid tumours has immense potential, but is challenging due to the small amount of available material. To address this, we present here a plug-based microfluidics platform for functional screening of drug combinations. Integrated Braille valves allow changing the plug composition on demand and enable collecting >1200 data points (56 different conditions with at least 20 replicates each) per biopsy. After deriving and validating efficient and specific drug combinations for two genetically different pancreatic cancer cell lines and xenograft mouse models, we additionally screen live cells from human solid tumours with no need for ex vivo culturing steps, and obtain highly specific sensitivity profiles. The entire workflow can be completed within 48 h at assay costs of less than US$ 150 per patient. We believe this can pave the way for rapid determination of optimal personalized cancer therapies.

UR - http://www.scopus.com/inward/record.url?scp=85048985572&partnerID=8YFLogxK

U2 - 10.1038/s41467-018-04919-w

DO - 10.1038/s41467-018-04919-w

M3 - Article

VL - 9

JO - Nature Communications

T2 - Nature Communications

JF - Nature Communications

SN - 2041-1723

IS - 1

M1 - 2434

ER -

Eduati F, Utharala R, Madhavan D, Neumann UP, Longerich T, Cramer T et al. A microfluidics platform for combinatorial drug screening on cancer biopsies. Nature Communications. 2018 jun 22;9(1). 2434. Beschikbaar vanaf, DOI: 10.1038/s41467-018-04919-w